Home » Topics » Endocrine/metabolic, BioWorld Science

Endocrine/metabolic, BioWorld Science
RSS

Novel diabetes treatments reported by Shaman

Feb. 4, 1997

Pfizer claims glycogen phosphorylase inhibitors

Feb. 4, 1997

Successful completion of phase I trial of aerosolized osteoporosis product

Feb. 3, 1997

Inhale/Lilly collaborate on pulmonary delivery of osteoporosis Rx

Feb. 3, 1997

Hypoglycemic/hypolipidemic agents from Sumitomo Metal

Feb. 3, 1997

Japanese researchers describe compounds for lipoprotein disorders

Feb. 3, 1997

FDA approves Teva drug

Jan. 31, 1997

FDA approves antidiabetic drug within 6 months of filing

Jan. 31, 1997

Biotech launches Diab II

Jan. 31, 1997

Shaman describes antidiabetic agents from natural source

Jan. 31, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 9, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...